CClinicalTrials.gg
CompletedNCT02465541Updated Sep 15, 2023

Gentle Yoga and Dietary Counseling in Improving Physical Function and Quality of Life in Stage I-II Endometrial Cancer Survivors

An interventional study of Gentle yoga therapy and counseling intervention in Obesity and Endometrial Carcinoma, sponsored by Ohio State University Comprehensive Cancer Center. Completed at 1 site in United States. Open to female participants. Per ClinicalTrials.gov, last updated 2023-09-15.

Sponsored by Ohio State University Comprehensive Cancer Center · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Jul 2013, registered May 2014).
Phase
Not applicable
Study type
Interventional
Enrollment
16
Allocation
Randomized
Sex
Female
01

Study summary

This randomized clinical trial studies how well gentle yoga and dietary counseling lifestyle change effects physical function and quality of life of endometrial cancer survivors. Gentle yoga and dietary counseling may help improve physical function and quality of life for stage I-II endometrial cancer survivors.

Read the detailed description

PRIMARY OBJECTIVES:

I. To determine the feasibility and efficacy of a combined lifestyle intervention (yoga + diet) to positively impact physical function and quality of life for endometrial cancer survivors.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Participants undergo onsite gentle yoga once weekly over 45-60 minutes for 8 weeks and home-based gentle yoga for 6 weeks. Participants also undergo dietary counseling over 8 weeks.

ARM II: Participants undergo enhanced usual care designed to educate on best practices for exercise, diet and lifestyle change once weekly for 14 weeks.

02

Conditions studied

  • Obesity
  • Endometrial Carcinoma

Keywords

  • Cancer Survivors
  • Yoga
  • Endometrial Cancer
03

In context

Endometrial Neoplasms

1,325 studies on the registry are indexed under Endometrial Neoplasms; 447 are open to participants now.

This study's enrollment of 16 is below the median of 70 across 941 interventional studies indexed under Endometrial Neoplasms.

Browse Endometrial Neoplasms studies →

Lead sponsor

Ohio State University Comprehensive Cancer Center is the lead sponsor of 369 studies on the registry; 81 are open to participants now.

Of its 38 completed or terminated interventional studies of FDA-regulated products, 19 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • English speaking
  • Previous diagnosis of grade 1 or 2, stage I or II endometrioid endometrial cancers ("type I cancers") as confirmed during surgical intervention for treatment
  • Overweight or obese (> 25 kg/m\^2)
  • Anytime from treatment
  • Treating oncologist consent
  • Primary physician consent to engage in physical activity unsupervised
  • Ambulatory or able to engage in walking for at least 15 minutes
  • Sedentary lifestyle, as engaging in less than 100 minutes structured aerobic walking, cycling or swimming per week

Exclusion criteria

Exclusion Criteria:

  • No prior type I endometrial cancer diagnosis
  • Prior diagnosis of other cancer
  • Currently (previous 6 months) engaged in structured exercise either aerobic or yoga based
  • Severe heart or systemic disease: evidence of documented myocardial infarction, chronic unstable angina, symptomatic congestive heart failure, uncontrolled hypertension
  • Severe musculoskeletal disease: severe muscle or joint disorders due to disease or trauma, amputations, or any condition that significantly impair physical capabilities, as defined by the physician
  • Non-ambulatory
  • Concurrent diagnosis of organic brain syndrome, dementia, mental retardation, or significant sensory deficit
  • Major mental illness (e.g., schizophrenia, major depressive disorder)
  • Unwilling to give consent
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Arm I (gentle yoga and dietary counseling)

    Participants undergo onsite gentle yoga once weekly over 45-60 minutes for 8 weeks and home-based gentle yoga for 6 weeks. Participants also undergo dietary counseling over 8 weeks.

    Procedure: Gentle yoga therapy · Other: counseling intervention · Other: quality-of-life assessment · Other: questionnaire administration

  • Active comparator
    Arm II (enhanced usual care)

    Participants undergo enhanced usual care designed to educate on best practices for exercise, diet and lifestyle change once weekly for 14 weeks.

    Other: educational intervention · Other: quality-of-life assessment · Other: questionnaire administration

Interventions

  • ProcedureGentle yoga therapy

    Mindfulness in Motion is a mindfulness based intervention that is an 8-10 week program for adults interested in learning a practical strategy for stress reduction, intended to be delivered on the worksite or home.

    Also known as: yoga

  • Othercounseling intervention

    Undergo dietary counseling that will include 10 (20-min) nutritional counseling sessions with a registered dietitian.

    Also known as: counseling and communications studies

  • Othereducational intervention

    Undergo enhanced usual care

    Also known as: intervention, educational

  • Otherquality-of-life assessment

    Ancillary studies

    Also known as: quality of life assessment

  • Otherquestionnaire administration

    Ancillary studies

06

What researchers measure

Primary outcomes

  1. Examine change from baseline in physical function as measured by the Short Physical Performance Battery (SPPB).

    Physical function will be assess using a SPPB walk performance assessment. Quality life will be assessed via the SF-36 and the Functional Assessment of Cancer Therapy-Endometrial FACT-EN.

    Time frame: Up to 14 weeks

Secondary outcomes

  1. Examine intervention feasibility using a composite assessment.

    Descriptive statistics for the feasibility measures will be calculated using recruitment, adherence, and retention rate.

    Time frame: Up to 14 weeks

Other outcomes

  1. Change from baseline in quality of life as measured by the FACT-G (Functional Assessment of Cancer Therapy: General)

    Time frame: Up to 14 weeks

  2. Change from baseline in mindfulness as measured by the 5 Factor mindfulness questionnaires (FFMQ)

    Time frame: Up to 14 weeks

07

Study locations

1 site
  • Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center
    Columbus, Ohio 43210, United States
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02465541
Lead sponsor
Ohio State University Comprehensive Cancer Center
Responsible party
Brian Focht (Principal Investigator, Ohio State University Comprehensive Cancer Center) — Principal investigator
First posted
Jun 8, 2015
Start date
Jul 23, 2013
Primary completion
Jun 10, 2014
Completion
Apr 27, 2022
Last update
Sep 15, 2023

Study contacts

Brian Focht, PhD, FACSM
principal investigator · Ohio State University Comprehensive Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion